Controlled release of lovastatin from poly(lactic- co-glycolic acid) nanoparticles for direct pulp capping in rat teeth

Int J Nanomedicine. 2017 Jul 31:12:5473-5485. doi: 10.2147/IJN.S138410. eCollection 2017.

Abstract

Statin at appropriate concentrations has been shown to induce odontoblastic differentiation, dentinogenesis, and angiogenesis. However, using a carrier to control statin release might reduce toxicity and enhance its therapeutic effects. The aim of this study was to prepare poly(d,l-lactide-co-glycolide acid) (PLGA) nanoparticles that contain lovastatin for application in direct pulp capping. The PLGA-lovastatin particle size was determined using dynamic light scattering measurements and transmission electron microscopy. In addition, the release of lovastatin was quantified using a UV-Vis spectrophotometer. The cytotoxicity and alkaline phosphatase (ALP) activity of PLGA-lovastatin nanoparticles on human dental pulp cells were investigated. Moreover, a real-time polymerase chain reaction (PCR) assay, Western blot analysis, and an enzyme-linked immunosorbent assay (ELISA) were used to examine the osteogenesis gene and protein expression of dentin sialophosphoprotein (DSPP), dentin matrix acidic phosphoprotein 1 (DMP1), and osteocalcin (OCN). Finally, PLGA-lovastatin nanoparticles and mineral trioxide aggregate (MTA) were compared as direct pulp capping materials in Wistar rat teeth. The results showed that the median diameter of PLGA-lovastatin nanoparticles was 174.8 nm and the cumulative lovastatin release was 92% at the 44th day. PLGA-lovastatin nanoparticles demonstrated considerably a lower cytotoxicity than free lovastatin at 5, 9, and 13 days of culture. For ALP activity, the ALP amount of PLGA-lovastatin (100 μg/mL) was significantly higher than that of the other groups for 9 and 13 days of culture. The real-time PCR assay, Western blot analysis, and ELISA assay showed that PLGA-lovastatin (100 μg/mL) induced the highest mRNA and protein expression of DSPP, DMP1, and OCN in pulp cells. Histological evaluation of the animal studies revealed that MTA was superior to the PLGA-lovastatin in stimulating the formation of tubular dentin in an observation period of 2 weeks. However, in an observation period of 4 weeks, it was evident that the PLGA-lovastatin and MTA were competitive in the formation of tubular reparative dentin and a complete dentinal bridge.

Keywords: PLGA; direct pulp capping; lovastatin.

MeSH terms

  • Alkaline Phosphatase / metabolism
  • Aluminum Compounds / metabolism
  • Animals
  • Calcium Compounds / metabolism
  • Cell Differentiation / drug effects
  • Delayed-Action Preparations / pharmacology
  • Dental Pulp / cytology
  • Dental Pulp Capping / methods*
  • Drug Combinations
  • Enzyme-Linked Immunosorbent Assay
  • Extracellular Matrix Proteins / genetics
  • Extracellular Matrix Proteins / metabolism
  • Humans
  • Lactic Acid / chemistry*
  • Lovastatin / pharmacokinetics*
  • Lovastatin / pharmacology
  • Molar, Third
  • Nanoparticles / administration & dosage
  • Nanoparticles / chemistry*
  • Osteogenesis / genetics
  • Oxides / metabolism
  • Phosphoproteins / genetics
  • Phosphoproteins / metabolism
  • Polyglycolic Acid / chemistry*
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rats, Wistar
  • Sialoglycoproteins / genetics
  • Sialoglycoproteins / metabolism
  • Silicates / metabolism

Substances

  • Aluminum Compounds
  • Calcium Compounds
  • Delayed-Action Preparations
  • Drug Combinations
  • Extracellular Matrix Proteins
  • Oxides
  • Phosphoproteins
  • Sialoglycoproteins
  • Silicates
  • dentin sialophosphoprotein
  • mineral trioxide aggregate
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
  • Lovastatin
  • Alkaline Phosphatase